These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16150246)

  • 61. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning.
    Wartofsky L
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1486-9. PubMed ID: 11932269
    [No Abstract]   [Full Text] [Related]  

  • 62. Recurrent differentiated thyroid cancer.
    Shaha AR
    Endocr Pract; 2012; 18(4):600-3. PubMed ID: 22849875
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cytokines: Application in recurrence appraisal for differentiated thyroid carcinoma and their relation with radioiodine ablation.
    Yang M; Yin Y; Zhang J; Yi W; Liu J; Chen D; Zhang H; Fan X; Zhang Y; Zhu M; Qin S; Lv Z; Yu F
    J Cell Biochem; 2021 Oct; 122(10):1350-1359. PubMed ID: 34143519
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-Term Follow-Up for Differentiated Thyroid Carcinoma Patients: A Reconsideration.
    van der Wardt RA; Persoon AC; Klein Hesselink EN; Links TP
    Thyroid; 2017 Mar; 27(3):475-476. PubMed ID: 28049373
    [No Abstract]   [Full Text] [Related]  

  • 65. Modern management of differentiated thyroid cancer.
    Cohen JB; Kalinyak JE; McDougall IR
    Cancer Biother Radiopharm; 2003 Oct; 18(5):689-705. PubMed ID: 14629818
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Thyroid cancer: a review.
    Baker KH; Feldman JE
    Oncol Nurs Forum; 1993; 20(1):95-104. PubMed ID: 8421653
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Treatment protocols and follow-up of differentiated thyroid carcinoma: results of a questionnaire sent to the Spanish Metabolic Therapy Units].
    Muros MA; Arbizu J; Abós MD; Mitjavilla M; Caballero-Calabuig E; Vallejo JA
    Rev Esp Med Nucl; 2011; 30(3):147-55. PubMed ID: 21439688
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Do all cancers need to be treated? The role of thyroglobulin in the management of thyroid cancer: the 2006 Hayes Martin lecture.
    Heller KS
    Arch Otolaryngol Head Neck Surg; 2007 Jul; 133(7):639-43. PubMed ID: 17638774
    [No Abstract]   [Full Text] [Related]  

  • 69. Treatment of iodine negative, thyroglobulin positive, thyroid cancer patients: do we miss the target when we shoot in the dark?
    Kabasakal L
    Nucl Med Commun; 2003 Jul; 24(7):739-41. PubMed ID: 12813190
    [No Abstract]   [Full Text] [Related]  

  • 70. Our experience from radioiodine-131 treatment and whole body scintigraphy findings in 357 patients with metastatic differentiated thyroid carcinoma after surgical ablation.
    Kraft O; Reznák I
    Hell J Nucl Med; 2006; 9(2):112. PubMed ID: 16894419
    [No Abstract]   [Full Text] [Related]  

  • 71. A review of the evidence base for the management of thyroid disease. A summary of the proceedings of the 8th annual evidence-based medicine day, Freeman Hospital, Newcastle, 4 November 2004.
    Cocks HC
    Clin Otolaryngol; 2005 Dec; 30(6):500-10. PubMed ID: 16402974
    [No Abstract]   [Full Text] [Related]  

  • 72. Thyroglobulin before ablative radioiodine therapy.
    Grünwald F; Menzel C; Biersack HJ
    Eur J Nucl Med; 2000 Apr; 27(4):461. PubMed ID: 10805121
    [No Abstract]   [Full Text] [Related]  

  • 73. Serum thyroglobulin measurements: clinical utility and technical limitations in the management of patients with differentiated thyroid carcinomas.
    Spencer CA
    Endocr Pract; 2000; 6(6):481-4. PubMed ID: 11155225
    [No Abstract]   [Full Text] [Related]  

  • 74. Thyroid Cancer in Pediatrics.
    Machac J
    Endocrinol Metab Clin North Am; 2016 Jun; 45(2):359-404. PubMed ID: 27241970
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Controversies in the follow-up and management of well-differentiated thyroid cancer.
    Ringel MD; Ladenson PW
    Endocr Relat Cancer; 2004 Mar; 11(1):97-116. PubMed ID: 15027888
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Well-differentiated thyroid cancer - are you overtreating your patients?
    Nixon IJ
    Endokrynol Pol; 2016; 67(1):60-6. PubMed ID: 26884117
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Management of papillary and follicular thyroid cancer.
    Jones MK
    J R Soc Med; 2002 Jul; 95(7):325-6. PubMed ID: 12091503
    [No Abstract]   [Full Text] [Related]  

  • 78. Monitoring for Thyroid Cancer Recurrence.
    Peiris AN
    Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469905
    [No Abstract]   [Full Text] [Related]  

  • 79. [Postoperative treatment of differentiated thyroid carcinoma with intermediate recurrence risk].
    Yang X; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Aug; 35(4):378-81. PubMed ID: 23987482
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Measurement of thyroglobulin or 131iodine scintigraphy in the after-care of patients with differentiated thyroid cancer].
    Schatz H; Horn W; Grebe SF; Müller H
    Dtsch Med Wochenschr; 1983 Nov; 108(45):1737-8. PubMed ID: 6313317
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.